Glycyrrhetinic acid food supplementation lowers serum potassium concentration in chronic hemodialysis patients

Kidney International

Volumn 76, Issue 8, 2009, Pages 877-884

  Farese, Stefan ^a   Kruse, Anja ^a   Pasch, Andreas ^a   Dick, Bernhard ^a   Frey, Brigitte M ^a   Uehlinger, Dominik E ^a   Frey, Felix J ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Dialysis; Food supplement; Glycyrrhetinic acid; Hyperkalemia; Serum potassium

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; GLYCYRRHETINIC ACID; HYDROCORTISONE; PLACEBO; POTASSIUM;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIALYSATE; DIARRHEA; DIET SUPPLEMENTATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART RATE VARIABILITY; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERKALEMIA; MALE; MEASUREMENT; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; SIDE EFFECT; WEIGHT GAIN;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; AGED; AGED, 80 AND OVER; ALDOSTERONE; BIOLOGICAL MARKERS; BLOOD PRESSURE; CORTISONE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; FOOD, FORTIFIED; GLYCYRRHETINIC ACID; HUMANS; HYDROCORTISONE; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POTASSIUM; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349656496     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.269     Document Type: Article

References (53)

1. Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial 2001; 14: 348-356.
2. Tzamaloukas AH, Avasthi PS. Temporal profile of serum potassium concentration in nondiabetic and diabetic outpatients on chronic dialysis. Am J Nephrol 1987; 7: 101-109.
3. Sandle GI, Gaiger E, Tapster S et al. Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (London) 1987; 73: 247-252.
4. Kaisar MO, Wiggins KJ, Sturtevant JM et al. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients. Am J Kidney Dis 2006; 47: 809-814.
5. Martin RS, Panese S, Virginillo M et al. Increased secretion of potassium in the rectum of humans with chronic renal failure. Am J Kidney Dis 1986; 8: 105-110.
6. Gerstman BB, Platt R. Use of sodium polystyrene sulfonate in sorbitol in the United States, 1985-1989. Am J Kidney Dis 1991; 18: 619-620.
7. Gruy-Kapral C, Emmett M, Santa Ana CA et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 1998; 9: 1924-1930.
8. Abraham SC, Bhagavan BS, Lee LA et al. Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. Am J Surg Pathol 2001; 25: 637-644.
9. Berlyne GM, Janabi K, Shaw AB. Dangers of resonium A in the treatment of hyperkalemia in renal failure. Lancet 1966; 1: 167-169.
10. Turnamian SG, Binder HJ. Regulation of active sodium and potassium transport in the distal colon of the rat. Role of the aldosterone and glucocorticoid receptors. J Clin Invest 1989; 84: 1924-1929.
11. Tomkins AM, Edmonds CJ. Electrical potential difference, sodium absorption and potassium secretion by the human rectum during carbenoxolone therapy. Gut 1975; 16: 277-284.
12. Sandle GI, Gaiger E, Tapster S et al. Enhanced rectal potassium secretion in chronic renal insufficiency: evidence for large intestinal potassium adaptation in man. Clin Sci (London) 1986; 71: 393-401.
13. Epple HJ, Schulzke JD, Schmitz H et al. Enzyme- and mineralocorticoid receptor-controlled electrogenic Na+ absorption in human rectum in vitro. Am J Physiol 1995; 269: G42-G48.
14. Odermatt A, Arnold P, Stauffer A et al. The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 1999; 274: 28762-28770.
15. Albiston AL, Obeyesekere VR, Smith RE et al. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105: R11-R17.
16. Funder JW, Pearce PT, Smith R et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583-585.
17. White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 1997; 18: 135-156.
18. Frey FJ, Odermatt A, Frey BM. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 451-458.
19. Serra A, Uehlinger DE, Ferrari P et al. Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria. J Am Soc Nephrol 2002; 13: 191-196.
20. Knochel JP, Dotin LN, Hamburger RJ. Pathophysiology of intense physical conditioning in a hot climate. I. Mechanisms of potassium depletion. J Clin Invest 1972; 51: 242-255.
21. Ferrari P, Sansonnens A, Dick B et al. In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. Hypertension 2001; 38: 1330-1336.
22. Atanasov AG, Ignatova ID, Nashev LG et al. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. J Am Soc Nephrol 2007; 18: 1262-1270.
23. Singhal PC, Desroches L, Mattana J et al. Mineralocorticoid therapy lowers serum potassium in patients with end-stage renal disease. Am J Nephrol 1993; 13: 138-141.
24. Turban S, Wang XY, Knepper MA. Regulation of NHE3, NKCC2, and NCC abundance in kidney during aldosterone escape phenomenon: role of NO. Am J Physiol Renal Physiol 2003; 285: F843-F851.
25. Mueller J. Aldosterone Stimulation in Vitro. I. Evaluation of Assay Procedure and Determination of Aldosterone-Stimulating Activity in a Human Urine Extract. Acta Endocrinol (Copenh) 1965; 48: 283-296.
26. Himathongkam T, Dluhy RG, Williams GH. Potassim-aldosterone-renin interrelationships. J Clin Endocrinol Metab 1975; 41: 153-159.
27. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
28. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
29. Funder JW. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology 2006; 147: 5564-5567.
30. Qin W, Rudolph AE, Bond BR et al. Transgenic model of aldosteronedriven cardiac hypertrophy and heart failure. Circ Res 2003; 93: 69-76.
31. Wilson P, Morgan J, Funder JW et al. Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart. Clin Sci (Lond) 2009; 116: 731-739.
32. Battaglia V, Brunati AM, Fiore C et al. Glycyrrhetinic acid as inhibitor or amplifier of permeability transition in rat heart mitochondria. Biochim Biophys Acta 2008; 1778: 313-323.
33. Wu X, Zhang L, Gurley E et al. Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways. Hepatology 2008; 47: 1905-1915.
34. Schnackenberg CG. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome. Curr Opin Investig Drugs 2008; 9: 295-300.
35. Escher G, Galli I, Vishwanath BS et al. Tumor necrosis factor alpha and interleukin 1beta enhance the cortisone/cortisol shuttle. J Exp Med 1997; 186: 189-198.
36. Hermanowski-Vosatka A, Balkovec JM, Cheng K et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005; 202: 517-527.
37. Escher G, Frey FJ, Frey BM. 11 beta-Hydroxysteroid dehydrogenase accounts for low prednisolone/prednisone ratios in the kidney. Endocrinology 1994; 135: 101-106.
38. Furuya R, Kumagai H, Sakao T et al. Potassium-lowering effect of mineralocorticoid therapy in patients undergoing hemodialysis. Nephron 2002; 92: 576-581.
39. Kim DM, Chung JH, Yoon SH et al. Effect of fludrocortisone acetate on reducing serum potassium levels in patients with end-stage renal disease undergoing haemodialysis. Nephrol Dial Transplant 2007; 22: 3273-3276.
40. Whalen JE, Cohen LH. Exogenous mineralocorticoid hormone improves predialysis hyperkalemia in anephric man. Proc Clin Dial Transplant Forum 1978; 8: 1-4.
41. Parker KL. Hormones and hormone antagonists. In: Hardmann JG, Limbird LE (eds). Goodmans & Gilman's "The Pharmalogical Basis of Therapeutics", 11th edn. McGraw-Hill: New York, 2006, pp 1594-1595.
42. Vogt W, Fischer I, Ebenroth S et al. [Pharmacokinetics of 9 -fluorhydrocortisone]. Arzneimittelforschung 1971; 21(Suppl): 1133-1143.
43. Nawrocki AR, Goldring CE, Kostadinova RM et al. In vivo footprinting of the human 11beta-hydroxysteroid dehydrogenase type 2 promoter: evidence for cell-specific regulation by Sp1 and Sp3. J Biol Chem 2002; 277: 14647-14656.
44. Alikhani-Koopaei R, Fouladkou F, Frey FJ et al. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest 2004; 114: 1146-1157.
45. Alikhani-Koupaei R, Fouladkou F, Fustier P et al. Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: functional characterization and relevance for salt sensitivity. FASEB J 2007; 21: 3618-3628.
46. Balazs Z, Schweizer RA, Frey FJ et al. DHEA induces 11 -HSD2 by acting on CCAAT/enhancer-binding proteins. J Am Soc Nephrol 2008; 19: 92-101.
47. van Rossum TG, Vulto AG, Hop WC et al. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 1999; 14: 1093-1099.
48. van Rossum TG, Vulto AG, Hop WC et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2432-2437.
49. Quattropani C, Vogt B, Odermatt A et al. Reduced activity of 11 betahydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 2001; 108: 1299-1305.
50. Vogt B, Dick B, N'Gankam V et al. Reduced 11beta-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome. J Clin Endocrinol Metab 1999; 84: 811-814.
51. Lee YS, Lorenzo BJ, Koufis T et al. Grapefruit juice and its flavonoids inhibit 11 beta-hydroxysteroid dehydrogenase. Clin Pharmacol Ther 1996; 59: 62-71.
52. Fuster D, Escher G, Vogt B et al. Furosemide inhibits 11betahydroxysteroid dehydrogenase type 2. Endocrinology 1998; 139: 3849-3854.
53. Odermatt A, Arnold P, Frey FJ. The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. J Biol Chem 2001; 276: 28484-28492.